{"entity":{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04980222 by Hoffmann-La Roche, with 46 participants enrolled, started 2022-03-22 and due to reach its primary completion in 2024-09-24. Interventions recorded: Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04980222","url":"https://clinicaltrials.gov/study/NCT04980222"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","t-cell-engager"],"targets":[],"drugs":["glofitamab","tocilizumab","doxorubicin","vincristine","prednisone","rituximab"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04980222","phase":"2","setting":"A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","sponsor":"Hoffmann-La Roche","started":"2022-03-22","startedType":"actual","yearReported":2026,"enrolled":46,"enrolledBasis":"registry","outcomes":[{"endpoint":"End of Treatment Complete Response (EOT CR) Rate","primary":true,"unit":"%","arms":[{"name":"Glofitamab + R-CHOP Immunochemotherapy","n":45,"value":73.3,"note":"95% CI 58.06 to 85.40; Figures from the ClinicalTrials.gov results section (first posted 2026-08-18), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04980222?tab=results"}]},"route":"/trials/nct04980222/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}